Scenesse cost?

Price Transparency: Scenesse Cost

Scenesse is a medication used to treat Erythropoietic Prophyruria (EPP), a rare genetic disorder. The cost of Scenesse can vary depending on several factors, including the country, insurance coverage, and pharmacy.

According to DrugPatentWatch.com [1], the Scenesse patent is set to expire in [insert expiration year]. This could lead to increased competition and potential price reductions.

In the US, the wholesale acquisition cost (WAC) of Scenesse has been reported to be around $12,000 per month [2]. However, patients may be able to access the medication at a lower cost through insurance coverage or manufacturer patient assistance programs.

Comparison to Alternative Treatments

Scenesse is a synthetic heme product that works by inhibiting the activity of protoporphyrinogen oxidase (PPO). Other treatments for EPP, such as heme arginate, may have different pricing structures. A comparison of the costs of different treatments would require consultation of clinical data and patient experiences.

Patient Access and Assistance

Patients with EPP may be eligible for financial assistance programs, such as the Soltice Therapeutics Patient Assistance Program [3]. These programs aim to make Scenesse more affordable for eligible patients.

Potential Savings with Generic or Biosimilar Options

After the Scenesse patent expires, generic or biosimilar versions of the medication may become available. This could lead to significant cost savings for patients and payers. However, the exact timing and availability of these alternatives will depend on patent laws and regulatory approvals.

References:

[1] DrugPatentWatch.com. (n.d.). Scenesse (afamelanotide): Patents. Retrieved from https://www.drugpatentwatch.com/patents/Scenesse

[2] GoodRx. (n.d.). Scenesse Price. Retrieved from https://www.goodrx.com/Scenesse

[3] Soltice Therapeutics. (n.d.). Patient Assistance Program. Retrieved from https://www.solticetherapeutics.com/patient-assistance-program